Literature DB >> 32619972

Radiographic and clinical outcomes using intraoperative magnetic resonance imaging for transsphenoidal resection of pituitary adenomas.

Rupa G Juthani1,2, Anne S Reiner3, Ankur R Patel2, Aimee Cowan2, Marie Roguski2,4, Katherine S Panageas3, Eliza B Geer5,6, Sasan Karimi7, Marc A Cohen8,6, Viviane Tabar2,6.   

Abstract

OBJECTIVE: The utility and safety of intraoperative MRI (iMRI) for resection of pituitary adenomas is not clearly established in the context of advances in endoscopic approaches. The goal in this study was to evaluate the safety and efficacy of iMRI for pituitary adenoma resection, with endoscopic transsphenoidal (ETS) versus microscopic transsphenoidal (MTS) approaches.
METHODS: Radiographic and clinical outcomes of all pituitary adenomas resected using iMRI between 2008 and 2017 at a single institution were retrospectively evaluated.
RESULTS: Of 212 tumors treated, 131 (62%) underwent further resection based on iMRI findings, resulting in a significant increase in gross-total resection on postoperative MRI compared with iMRI (p = 0.0001) in both ETS and MTS groups. iMRI increased rates of gross-total resection for cavernous sinus invasion Knosp grades 1 and 2, but not in Knosp ≥ 3 across treatment groups (p < 0.0001). The extent of resection on postoperative MRI was significantly correlated with increased progression-free survival (p < 0.0001). Initial hormone remission off medical therapy was achieved in 64%, with a significantly higher rate of remission in tumors resected via the ETS approach (81%) compared with the MTS approach (55%) (p = 0.02). The rate of persistent new hormone deficit was low at 8%, including a 2.8% rate of permanent diabetes insipidus, and 45% of patients had improvement in preoperative hormone deficit following surgery. Serious postoperative complications including CSF leaks requiring reoperation were rare at 1%, with no postoperative infections.
CONCLUSIONS: These results suggest that iMRI is a safe and effective method of increasing the extent of resection for pituitary adenomas while preserving hormone function. When paired with the endoscope, iMRI may offer the ability to tailor more aggressive removal of tumors while optimizing pituitary function, resulting in high rates of secretory hormone remission. Secretory tumors and adenomas with Knosp grade < 3 cavernous sinus invasion may benefit most from the use of iMRI.

Entities:  

Keywords:  ACTH = adrenocorticotropic hormone; CSI = cavernous sinus invasion; DI = diabetes insipidus; EOR = extent of resection; ETS = endoscopic transsphenoidal; GH = growth hormone; GTR = gross-total resection; MTS = microscopic transsphenoidal; NFA = nonfunctioning adenoma; NTR = near-total resection; PFS = progression-free survival; PRL = prolactin; RFS = recurrence-free survival; STR = subtotal resection; VF = visual field; iMRI = intraoperative MRI; intraoperative MRI; pituitary adenoma; pituitary endocrine outcomes; pituitary extent of resection; pituitary surgery; secretory adenoma; transsphenoidal

Year:  2020        PMID: 32619972     DOI: 10.3171/2020.4.JNS20178

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Magnetic resonance imaging characteristics predict pituitary function in non-functional pituitary macro-adenoma undergoing trans-sphenoidal surgery.

Authors:  Behrooz Hassani; Nahid Hashemi-Madani; Manizhe Ataee Kachuee; Mohammad E Khamseh
Journal:  BMC Med Imaging       Date:  2022-04-01       Impact factor: 1.930

2.  Impact of Intraoperative Magnetic Resonance Imaging (i-MRI) on Surgeon Decision Making and Clinical Outcomes in Cranial Tumor Surgery.

Authors:  Krishnapundha Bunyaratavej; Rungsak Siwanuwatn; Lawan Tuchinda; Piyanat Wangsawatwong
Journal:  Asian J Neurosurg       Date:  2022-08-24

3.  A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years.

Authors:  Yu Zhang; Yuqi Luo; Xin Kong; Tao Wan; Yunling Long; Jun Ma
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.